This article is more than 5 years old. Information may no longer be current.
VIDEO: More data needed to assess long-term benefits of neoadjuvant regimen for HER-2 positive breast cancer
Click Here to Manage Email Alerts
NEW ORLEANS — Clifford A. Hudis, MD, FACP, chief of the breast medicine service at Memorial Sloan Kettering Cancer Center, discusses the potential implications of the I-SPY 2 trial.
The trial, results of which were presented at the American Association for Cancer Research Annual Meeting, tested a new approach to drug development in breast cancer.
“The simple idea here is that, by selecting subsets of patients and giving them new targeted therapies in a controlled setting, one can quickly see whether the drug or combination has promise,” Hudis, who will take over as CEO of ASCO on June 27, told HemOnc Today.
I-SPY 2 showed neoadjuvant treatment with ado-trastuzumab emtansine (Kadcyla, Genentech) plus pertuzumab (Perjeta, Genentech) was more beneficial for women with HER-2–positive disease than the current standard of care, paclitaxel plus trastuzumab (Herceptin, Genentech).
“As we evaluate the results of I-SPY 2, and we see a higher pathologic complete response rate for this combination, we’re still going to be left needing more data that lets us assess the long-term impact and benefits of this approach,” Hudis said.
Editor’s note: On April 20, we corrected this article to accurately reflect the affiliation Clifford A. Hudis, MD, FACP, has with ASCO. Hudis will become the society’s CEO on June 27. The Editors regret this error.